Shares of Catalyst Pharmaceuticals Inc. CPRX rose 1.34% to $23.40 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.19% to 19,692.33 and the Dow Jones Industrial Average DJIA rising 0.71% to 44,873.28.

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Fintel reports that on February 4, 2025, Baird initiated coverage of Catalyst Pharmaceuticals (NasdaqCM:CPRX) with a Outperform recommendation. Analyst Price Forecast Suggests 47.68% Upside As of January 29,

Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target of $28.00. The firm highlighted Catalyst Pharma's successful commercialization of drugs for rare neurological diseases as the basis for the positive outlook.